Skip to Main Content

Joscelyn Cekola "Josie"
Boucher

  • Executive Partner

I love being part of the venture capital community, bringing innovative new technologies to the market through my work with start-up companies and venture capitalists. I offer both great value and graceful escort through a competitive and active space — whether for emerging growth companies at any stage or investors seeking new tech acquisitions that align with their mission and values.

Few attorneys possess Josie Boucher’s broad acumen in venture capital transactions, particularly in structuring private securities offerings, and handling the myriad of issues inherent in exit transactions for venture-backed companies with complex capitalization structures. Representing both emerging growth companies and individual, fund and corporate investors in venture capital financing transactions, Josie shines in all aspects of corporate and securities law.

  • Advises clients on transaction structure, strategy and general legal matters.
  • Represented a cancer therapeutic development company in a various series of convertible note and preferred stock financings, culminating in a $60M Series D financing round, and ultimate initial public offering.
  • Represented a medical device company in an $8 million Series A preferred stock financing.
  • Represented a cancer diagnostic company in a $2 million convertible debt offering and $5 million Series A financing.
  • Represented a dental medical device company in a $4 million Series A preferred stock financing.
  • Represented a biomedical company in the conversion of the company from a limited liability company to a corporation and subsequent
  • Advises clients on transaction structure, strategy and general legal matters.
  • Represented a cancer therapeutic development company in a various series of convertible note and preferred stock financings, culminating in a $60M Series D financing round, and ultimate initial public offering.
  • Represented a medical device company in an $8 million Series A preferred stock financing.
  • Represented a cancer diagnostic company in a $2 million convertible debt offering and $5 million Series A financing.
  • Represented a dental medical device company in a $4 million Series A preferred stock financing.
  • Represented a biomedical company in the conversion of the company from a limited liability company to a corporation and subsequent $5 million Series A preferred stock financing.
  • Represented an agricultural biotechnology company in various series of convertible note and preferred stock financings, including a $18 million Series D preferred stock financing.
  • Represented a biotech company in a $1 million common stock financing.
  • Represented a drug development company in its conversion from a corporation into a limited liability company and $32.5 million Series D preferred equity financing.
  • Represented a drug development company in the spin out of an asset and subsequent $20 million Series A-1 preferred stock financing and $40 million Series A-2 preferred stock financing.
  • Represented a clinical stage biopharmaceutical company in its initial public offering.
  • Represented a $20 million venture capital fund in fund formation and investment matters.
  • Represented a private equity fund with over $1 billion in capital under management in various growth capital investments in emerging growth companies.
  • Represented a family office in preferred equity investments in innovative food companies.
  • Negotiated a License Agreement on behalf of a cancer therapeutic drug development company with a publicly traded biotechnology company.
  • Negotiated a cross-license agreement on behalf of a cardiac monitoring device company with a Fortune 500 medical device company.
  • Negotiated a license agreement on behalf of a biotechnology company with an Indian manufacturer of xylitol.
  • Negotiated distribution and manufacturing agreements on behalf of a publicly traded cardiac medical device company.
  • Negotiated a collaboration agreement on behalf of an agricultural biotechnology company with multinational publicly traded agrochemical and agricultural biotechnology company.
  • Negotiated a toll manufacturing agreement on behalf of an agricultural biotechnology company with an Italian manufacturer.
  • Represented a media company in its acquisitions of an Indian-based internet company and a venture-backed internet company for automotive enthusiasts.
  • Represented a media company in acquisition of a specialty newspaper line and magazine.
  • Represented an aftermarket automotive parts supplier in numerous acquisitions and divestures.
  • Represented and advised a Fortune 500 publicly traded company in connection with internal international restructuring transactions.
Image for Joscelyn “Josie” Cekola Boucher

Joscelyn Cekola "Josie"
Boucher

  • Executive Partner
Kalamazoo

My admin

I love being part of the venture capital community, bringing innovative new technologies to the market through my work with start-up companies and venture capitalists. I offer both great value and graceful escort through a competitive and active space — whether for emerging growth companies at any stage or investors seeking new tech acquisitions that align with their mission and values.

Few attorneys possess Josie Boucher’s broad acumen in venture capital transactions, particularly in structuring private securities offerings, and handling the myriad of issues inherent in exit transactions for venture-backed companies with complex capitalization structures. Representing both emerging growth companies and individual, fund and corporate investors in venture capital financing transactions, Josie shines in all aspects of corporate and securities law.